Second, three antigens were chosen for loading of separate DC batches.16 Next to WT1, which is very frequently overexpressed in AML and the most prominent antigen in vaccination trials for AML, both for DC vaccination10, 17, 18 and for peptide vaccination,5 we decided to add a second LAA in order to broaden anti‐leukaemic responses and to decrease the possibility of immune escape. This evidence concerns the gene WT1 and acute myeloid leukemia.